Viking Therapeutics to Report Financial Results for Second Quarter 2023 on July 26, 2023

Rhea-AI Summary

Viking Therapeutics, Inc. will release its financial results for the second quarter of 2023 on July 26. The company, focused on developing therapies for metabolic and endocrine disorders, will host a conference call at 4:30 p.m. Eastern Time to discuss the results and general corporate updates. A telephone replay will be available until August 2, and the conference call can also be accessed live via the internet.

Conference Call Scheduled for Wednesday, July 26 at 4:30 p.m. Eastern Time 

SAN DIEGO, July 19, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that the company will release financial results for the second quarter 2023 after the market close on Wednesday, July 26, 2023.

The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. Eastern Time on Wednesday, July 26, 2023. To participate on the conference call, please dial (844) 850-0543 from the U.S. or (412) 317-5199 from outside the U.S. In addition, following the completion of the call, a telephone replay will be accessible until August 2, 2023, by dialing (877) 344-7529 from the U.S. or (412) 317-0088 from outside the U.S. and entering replay access code #7363621. Those interested in listening to the conference call live via the internet may do so by visiting the Webcasts page of Viking's website at http://ir.vikingtherapeutics.com/webcasts. An archive of the webcast will also be available on the Webcasts page of the company's website for 30 days.

About Viking Therapeutics, Inc. 

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. The company's clinical programs include VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is currently being evaluated in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company is also developing VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. Data from a Phase 1 trial evaluating VK2735 (dosed subcutaneously) for metabolic disorders demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit. The company also recently initiated a Phase 1 study to evaluate an oral formulation of VK2735. In the rare disease space, the company is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). VK0214 is currently being evaluated in a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD. The company holds exclusive worldwide rights to a portfolio of five therapeutic programs, including VK2809 and VK0214, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated.

For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com. Follow Viking on Twitter @Viking_VKTX.

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/viking-therapeutics-to-report-financial-results-for-second-quarter-2023-on-july-26-2023-301879000.html

SOURCE Viking Therapeutics, Inc.

FAQ

When will Viking Therapeutics release its financial results for the second quarter of 2023?

Viking Therapeutics will release its financial results for the second quarter of 2023 on July 26.

What is Viking Therapeutics focused on?

Viking Therapeutics is focused on the development of novel therapies for metabolic and endocrine disorders.

When is the conference call scheduled?

The conference call is scheduled for Wednesday, July 26 at 4:30 p.m. Eastern Time.

How can I participate in the conference call?

To participate in the conference call, dial (844) 850-0543 from the U.S. or (412) 317-5199 from outside the U.S.

Will there be a telephone replay available?

Yes, a telephone replay will be accessible until August 2, 2023. Dial (877) 344-7529 from the U.S. or (412) 317-0088 from outside the U.S. and enter replay access code #7363621.

Can I listen to the conference call live via the internet?

Yes, you can listen to the conference call live via the internet by visiting the Webcasts page of Viking's website at http://ir.vikingtherapeutics.com/webcasts.

Will there be an archive of the webcast available?

Yes, an archive of the webcast will be available on the Webcasts page of the company's website for 30 days.